Price negotiation (status as of 23rd Oct 2013) Total
Early benefit assessment procedure completed with additional benefit 1 35
Thereof: Completed net price negotiations 2 and publication of manufacturer rebate in Lauer-Taxe 3 21
Thereof: Ongoing net price negotiations 14
Focus on comparator choice and direct evidence
Not using (one of) the appropriate comparator(s) set by GBA leads to a "no additional benefit" result. Early alignment with GBA on comparator selection is highly recommended in order to design appropriate head-to-head trials which resonate with GBA.
Focus on hard endpoints

1
It is highly recommended to focus demonstration of additional benefit in the dossier on patient-relevant (hard) endpoints (morbidity, mortality, safety and QoL) and/or well-justified surrogate endpoints in order to maximize the extent of additional benefit.
Patient segmentation as evaluation tool
Defining patient subpopulations in the dossier has been used by IQWiG and GBA to interpret a lower level of additional benefit. Ensure that all relevant sub-populations have robust and statistically significant clinical endpoints to support reimbursement.
GBA and IQWiG independence in decision making
GBA and IQWiG do act independently. Do not expect them to follow other European assessment results (e.g. by HAS or NICE).
No methodological standard for definition of additional benefit level
There is no standard methodology used by GBA to define additional benefit levels. Thus, a forecast of the likely outcome of a benefit assessment is difficult.
Use the consultation service of GBA to clarify all questions about comparator, study design, relevant endpoints and patient populations. But be aware that the information provided by the GBA in the consultations is not legally binding.
3 4 5
In 2011, the AMNOG law changed the price-setting procedure for drugs in Germany.
Manufacturers are now required to submit a dossier to the Federal Joint Committee (GBA) for newly launched or, upon specific request, already marketed products. The GBA decides on the level of additional benefit which impacts the reimbursement price negotiations with German sick funds. The objectives of this study were thus to 1) identify ways in which manufacturers can optimize the benefit assessment outcomes, and 2) analyze correlations between additional benefit, budget impact and negotiated rebate.
To achieve objective 1, assessments by the GBA and the Institute for Quality and Efficiency in Healthcare (IQWiG) were scanned for key trends. To achieve objective 2, list and post-negotiation prices were extracted from the Lauer-Taxe (German price database). Those agents that had so far completed net price negotiations were mapped against additional benefit and the budget impact (annual therapy costs as stated in GBA assessment).
Background and Objectives Methods
Within one year after the GBA decision on the granted level of additional benefit, the final reimbursed price (net price) must be negotiated between manufacturer and GKV-SV. If there is no agreement possible after the 5th meeting in the year, an arbitration panel defines the net price based on international prices with retroactive effect from the 13th month of launch. However, the initial list price remains.
ISPOR 2013, 2-6 November, Dublin Learnings from completed net price negotiations
Of the 62 completed assessments, in 35 cases manufacturers of assessed products were able to demonstrate an additional benefit of their product against the clinical comparator and were therefore enabled to enter net price negotiations with the main association of sick funds in Germany (GKV-SV).
Evidence of additional benefit is a prerequisite for the net price negotiations. Products without additional benefit are grouped into reference price groups. If a reference price group is not possible, the net price must not exceed the annual treatment cost of the appropriate comparator.
Net price negotiations follow a clear agenda as outlined in the general agreement between pharmaceutical industry and GKV-SV Manufacturers should start early (already ahead of dossier preparation) with the development of a solid price strategy including the tactics to discuss the impact on final net price of the following main product characteristics: additional benefit level granted by GBA (for different patient subgroups), budget impact, price and market size of the clinical comparator and any other relevant price comparators, European reference prices. In addition, manufacturers should determine negotiation strategies on basis of variable attributes like "Praxisbesonderheit", prescription forecast/volume agreement, contract duration, inclusion/ exclusion of the mandatory rebate.
Rebate negotiation does not depend only on level of additional benefit
The additional benefit level is the door opener to price negotiations. However, there is no obvious correlation between additional benefit level as granted by GBA, the comparator price and the final net price (composed by list price reduction, mandatory rebate and/or negotiated rebate) of the products.
Budget impact is an important driver in the negotiation
Target population size, annual therapy costs per patient and the drug price are the main influencers of budget impact. It is important to clearly define the target population in order for GKV-SV to accept this during negotiations. While budget impact compared to clinical comparator alone seems not to have direct linear impact on discount level negotiated with GKV-SV, budget impact compared to other relevant competitors on the market (= further pricing comparators) is considered in price negotiations. 
